Enanta Pharmaceuticals, Inc. ENTA

11.88 (0.12) (1.00%) as of 25 Sep
Market cap
$349.5M
P/E
0.0×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Sep '16 Sep '17 Sep '18 Sep '19 Sep '20 Sep '21 Sep '22 Sep '23 Sep '24 Sep '25
Revenue
88.27 102.81 206.63 205.20 122.47 97.07 86.16 79.20 67.64 65.32
Revenue Growth
(45.13%) 16.48% 100.97% (0.69%) (40.31%) (20.74%) (11.24%) (8.07%) (14.61%) (3.42%)
Gross Profit
88.27 102.81 206.63 205.20 122.47 97.07 86.16 79.20 67.64 65.32
R&D Expenses
40.46 57.45 94.86 142.21 136.76 174.11 164.52 163.52 131.48 106.74
SG&A Expenses
16.97 20.75 23.44 26.25 27.36 32.54 45.48 52.89 57.85 43.93
Operating Income
30.84 24.61 88.33 36.74 (41.64) (109.57) (123.84) (137.21) (121.69) (85.35)
Non-operating Income/Expense
1.72 2.33 4.79 8.82 6.62 1.99 1.66 6.21 3.90 1.80
Non-operating Interest Expenses
1.74 2.53 4.85 8.82 6.47 2.02 1.57 5.15 10.94 7.68
EBT
32.56 26.95 93.12 45.56 (35.02) (107.58) (122.19) (130.99) (117.79) (83.55)
Income Tax Provision
10.89 9.24 21.17 (0.83) 1.15 (28.58) (0.43) 2.82 (1.74) (1.66)
Income after Tax
21.67 17.71 71.96 46.38 (36.17) (79.00) (121.75) (133.82) (116.04) (81.89)
Net Income Common
21.67 17.71 71.96 46.38 (36.17) (79.00) (121.75) (133.82) (116.04) (81.89)
EPS (Basic)
1.14 0.93 3.74 2.37 (1.81) (3.92) (5.91) (6.38) (5.48) (3.84)
EPS (Diluted)
1.13 0.91 3.48 2.21 (1.81) (3.92) (5.91) (6.38) (5.48) (3.84)
Shares (Basic, Weighted)
18.93 19.07 19.26 19.58 19.94 20.17 20.60 20.97 21.16 21.34
Shares (Diluted, Weighted)
19.22 19.41 20.65 20.97 19.94 20.17 20.60 20.97 21.16 21.34
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBIT Margin
34.94% 23.94% 42.75% 17.90% (34.00%) (112.88%) (143.74%) (173.23%) (179.92%) (130.65%)
EBT margin
36.89% 26.21% 45.07% 22.20% (28.59%) (110.82%) (141.82%) (165.39%) (174.15%) (127.90%)
Net Profit Margin
24.55% 17.23% 34.82% 22.60% (29.53%) (81.38%) (141.31%) (168.95%) (171.58%) (125.36%)
Free Cash Flow Margin
35.20% 48.77% 12.70% 32.16% 4.61% (72.88%) (100.87%) (141.67%) (142.99%) (49.24%)
EBITDA
34.01 27.45 90.01 35.66 (37.69) (104.12) (119.70) (137.69) (120.49) (80.26)
EBIT
30.84 24.61 88.33 36.74 (41.64) (109.57) (123.84) (137.21) (121.69) (85.35)
Income from Continuous Operations
21.67 17.71 71.96 46.38 (36.17) (79.00) (121.75) (133.82) (116.04) (81.89)
Consolidated Net Income/Loss
21.67 17.71 71.96 46.38 (36.17) (79.00) (121.75) (133.82) (116.04) (81.89)
EPS (Basic, from Continuous Ops)
1.14 0.93 3.74 2.37 (1.81) (3.92) (5.91) (6.38) (5.48) (3.84)
EPS (Basic, Consolidated)
1.14 0.93 3.74 2.37 (1.81) (3.92) (5.91) (6.38) (5.48) (3.84)
EPS (Diluted, from Cont. Ops)
1.13 0.91 3.48 2.21 (1.81) (3.92) (5.91) (6.38) (5.48) (3.84)
Shares (Diluted, Average)
19.22 19.41 20.65 20.97 19.94 20.17 20.60 20.97 21.16 21.34
EPS (Diluted, Consolidated)
1.13 0.91 3.48 2.21 (1.81) (3.92) (5.91) (6.38) (5.48) (3.84)
EBITDA Margin
38.53% 26.70% 43.56% 17.38% (30.77%) (107.26%) (138.93%) (173.84%) (178.15%) (122.86%)
Operating Cash Flow Margin
40.57% 51.21% 14.14% 34.80% 5.79% (72.11%) (98.40%) (130.24%) (116.45%) (29.50%)

Fold the line items

In millions of $ except per-share values · columns are period end dates